409 completed, 112 terminated, 105 recruiting, 73 active not recruiting. 816 Phase 1, 282 Phase 2.
Follow Glioblastoma: new trials by email Literature Review of Glioblastoma trials Research Report on Glioblastoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT) - Glioblastoma, High-Grade Glioma (WHO III-IV) | Phase 1 / Phase 2 | Not yet recruiting | Sabine Mueller, MD, PhD | 97 | 2027-06-01 | 2026-09-15 |
| Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 41 | 2027-06-01 | 2026-10-05 |
| DLL3 CAR-T Therapy Targeting Brain Tumors 4SCAR DLL3 T cells - Glioblastoma of Cerebellum | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-11-02 |
| FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma Biospecimen Collection, Computed Tomography, Dexamethasone - Glioblastoma, Malignant Glioma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 24 | 2027-02-17 | 2026-08-27 |
| NG101m Adjuvant Therapy in Glioblastoma Patients Intensity-modulated radiation therapy, Temozolomide, NG101m - Glioblastoma Multiforme | Phase 1 / Phase 2 | Not yet recruiting | NeuGATE Theranostics | 52 | 2027-01-01 | 2025-10-21 |
| CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) CM93 - Glioblastoma | Phase 1 | Not yet recruiting | Crimson Biopharm Inc. | 72 | 2027-01-01 | 2024-08-21 |
| IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG) Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells - High-grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 1 | Not yet recruiting | University of Florida | 24 | 2027-01-01 | 2026-10-30 |
| Immune Modulatory DC Vaccine Against Brain Tumor Immunomodulatory DC vaccine to target DIPG and GBM - Diffuse Intrinsic Pontine Glioma or Glioblastoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-10-30 |
| Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab - Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 30 | 2026-12-04 | 2026-06-12 |
| A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma B-cell vaccination - Glioblastoma | Phase 1 | Not yet recruiting | Catalina Lee Chang | 25 | 2026-12-01 | 2026-09-25 |
| A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) SRN-101 - Recurrent High Grade Gliomas, Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | Siren Biotechnology | 40 | 2026-12-01 | 2026-10-28 |
| OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma CT-179 - Recurrent Glioblastoma, Newly Diagnosed MGMT Unmethylated Glioblastoma | Phase 1 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 54 | 2026-12-01 | 2026-10-28 |
| TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma 5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound - Glioblastom WHO Grade 4, GBM | Phase 1 | Recruiting | Alpheus Medical, Inc. | 30 | 2026-10-29 | 2026-10-09 |
| Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence Entacapone, Bevacizumab, Placebo - Glioblastoma | Phase 1 / Phase 2 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 96 | 2026-10-01 | 2026-09-21 |
| A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers AL58805, AL3818, Temozolomide (TMZ) - Endometrial Neoplasms, Ovarian Neoplasms | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | 138 | 2026-09-01 | 2026-09-10 |
| Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | BreakBio Corp | 10 | 2026-09-01 | 2026-08-19 |
| A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma NK Cells - Phase 1, NK Cell | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-08-21 | 2026-08-25 |
| BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma hEGFRvIII-CD3 (BRiTE) - Newly Diagnosed Glioblastoma, Recurrent Glioblastoma | Phase 1 | Recruiting | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 18 | 2026-08-17 | 2026-08-18 |
| Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC) 203Pb-RMX-VHPIB injection, SPECT/CT Imaging - Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | Radiomedix, Inc. | 20 | 2026-08-15 | 2026-08-07 |
Showing 20 of 816. Sign in to see all of them.
Brain Neoplasms (268) · Glioma (267) · Gliosarcoma (241) · Astrocytoma (233) · Oligodendroglioma (146) · Central Nervous System Neoplasms (127) · Ependymoma (63) · Neoplasms (57) · Medulloblastoma (43) · Melanoma (32) · Recurrence (32) · Carcinoma, Non-Small-Cell Lung (29) · Breast Neoplasms (28) · Neuroectodermal Tumors, Primitive (28)
Neoplasms, Glandular and Epithelial (814) · Neoplasms by Histologic Type (812) · Neoplasms, Nerve Tissue (811) · Neuroectodermal Tumors (811) · Neoplasms, Germ Cell and Embryonal (810) · Neoplasms, Neuroepithelial (806) · Neoplasms (759) · Astrocytoma (583) · Glioma (549) · Neoplasms by Site (373) · Nervous System Diseases (325) · Nervous System Neoplasms (322) · Brain Diseases (287) · Central Nervous System Diseases (286) · Central Nervous System Neoplasms (195)
Temozolomide (178) · Radiotherapy (90) · Bevacizumab (44) · Radiation (39) · Magnetic Resonance Spectroscopy (23) · Nivolumab (20) · pembrolizumab (20) · Surgical Procedures, Operative (19) · Irinotecan (18) · Carboplatin (16) · Carmustine (16) · Cyclophosphamide (14) · Radiosurgery (14) · Radiotherapy, Intensity-Modulated (13) · Specimen Handling (13)
National Cancer Institute (NCI) (68) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (24) · M.D. Anderson Cancer Center (23) · City of Hope Medical Center (20) · Duke University (16) · Novartis Pharmaceuticals (13) · Jonsson Comprehensive Cancer Center (12) · Northwell Health (10) · Case Comprehensive Cancer Center (9) · Celgene (8) · Memorial Sloan Kettering Cancer Center (8) · Northwestern University (8) · University of Florida (8) · Washington University School of Medicine (8) · New Approaches to Brain Tumor Therapy Consortium (7)
United States (600) · China (48) · Spain (43) · France (41) · Germany (37) · Canada (31) · Australia (29) · United Kingdom (29) · Switzerland (26) · Netherlands (25) · Italy (23) · Belgium (16) · Denmark (11) · Israel (11) · South Korea (11)
John Boockvar, MD (7) · Annick Desjardins, MD (6) · Behnam Badie (6) · Daniel Landi, MD (6) · Darell D. Bigner, MD, PhD (6) · David A. Reardon, MD (6) · Asha Das, MD (4) · David Peereboom, MD (4) · Henry S. Friedman, MD (4) · Howard A. Fine, MD (4) · Jana L Portnow (4) · Jana Portnow (4)
PMID 12749708, PMID 23377664, PMID 23545055, PMID 32078016, PMID 35468680, PMID 37142373, PMID 41218853, PMID 10394416, PMID 11410496, PMID 12573762, PMID 12721262, PMID 12749710, PMID 14670747, PMID 14769136, PMID 15292713, PMID 15667958, PMID 15758009, PMID 16012795, PMID 16061868, PMID 16170172, PMID 16192602, PMID 16520474, PMID 16877733, PMID 16914578, PMID 17264335, PMID 17470857, PMID 17560737, PMID 17694310, PMID 18048828, PMID 18056189, PMID 18056194, PMID 18094423, PMID 18215105, PMID 18359865, PMID 18391430, PMID 18470481, PMID 18477765, PMID 18723297, PMID 19248046, PMID 19289491, PMID 19533025, PMID 19534336, PMID 19725960, PMID 19760366, PMID 19768386, PMID 19945857, PMID 20063115, PMID 20821342, PMID 20864273, PMID 21377994
P30CA033572 (14), U01CA062475 (11), U01CA137443 (8), UM1CA137443 (8), 2023 (7), 2017 (6), U01CA062399 (6), U10CA025224 (6), U01CA081457 (5), 2018 (4), P30CA060553 (4), U10CA180821 (4), UM1CA081457 (4), 2015 (3), 2019 (3)